PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Antineoplastic Agents, Immunological
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
B7-H1 Antigen
/ antagonists & inhibitors
Carcinoma, Transitional Cell
/ drug therapy
Clinical Trials as Topic
Humans
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Survival Analysis
Treatment Outcome
Tumor Microenvironment
/ drug effects
Urologic Neoplasms
/ drug therapy
Co-inhibitory
Co-stimulatory
Immunotherapy
T-cell exhaustion
Tumor micro-environment
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
20
09
2018
revised:
14
01
2019
accepted:
17
03
2019
pubmed:
22
4
2019
medline:
28
3
2020
entrez:
22
4
2019
Statut:
ppublish
Résumé
Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several years, both in the second-line and first-line for cisplatin-ineligible patients. Those who respond often do so durably; however, response rates in the first line are 23% to 24%, and are lower in the second line. With a focus on urothelial carcinoma, this review discusses the tumor microenvironment and its negative influence on anti-tumor immunity, as well as measures to counteract immune suppression or evasion. The review then describes a range of current clinical trials implementing these measures in the form of programmed death-combination therapy, specifically in advanced bladder and urothelial cancers.
Identifiants
pubmed: 31005473
pii: S1558-7673(18)30684-0
doi: 10.1016/j.clgc.2019.03.009
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e618-e626Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.